Biotech company ImClone Systems Inc. said late Sunday it expects to disclose results of a Phase III study of a metastatic colorectal cancer treatment before the end of the week, so it is withdrawing from a previously scheduled investment conference.

The company was scheduled to present at the JPMorgan Healthcare Conference.

Results from the Phase III trial on Erbitux plus Folfiri, known as the Crystal study, are currently being reviewed by statisticians and independent investigators.